Neuropeptide Y polymorphism significantly magnifies diabetes and cardiovascular disease risk in obesity: the Hoorn Study

U. Jaakkola, J. Kallio, R.J. Heine, M.G.A.A.M. Nijpels, L.M. Hart, J.A. Maassen, L.M. Bouter, C.D.A. Stehouwer, J.M. Dekker

Research output: Contribution to journalArticleAcademicpeer-review

55 Downloads (Pure)


The leucine7 to proline7 (Leu7Pro) polymorphism in preproneuropeptide Y (preproNPY) has been associated with accelerated atherosclerosis and type II diabetes, both of which are obesity-related diseases. The current study evaluated the impact of obesity on the disease risk linked to the Leu7Pro polymorphism of preproNPY in 393 elderly subjects. In 6 years follow-up, the polymorphism alone did not change the risk for abnormal glucose regulation, while obesity was associated with a significant 3-fold risk (odds ratio (OR) 2.95; 95% confidence interval (CI) 1.81-4.81, P
Original languageEnglish
Pages (from-to)150-152
Number of pages3
JournalEuropean Journal of Clinical Nutrition
Issue number1
Publication statusPublished - 2009

Cite this